Search

Your search keyword '"Masi G."' showing total 2,009 results

Search Constraints

Start Over You searched for: Author "Masi G." Remove constraint Author: "Masi G."
2,009 results on '"Masi G."'

Search Results

51. A fitness model for the Italian Interbank Money Market

52. Physics of the GRB 030328 afterglow and its environment

53. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

54. The host of GRB 030323 at z=3.372: a very high column density DLA system with a low metallicity

55. A New SU UMa-Type Dwarf Nova, QW Serpentis (= TmzV46)

56. Superhumps in Cataclysmic Binaries. XXIV. Twenty More Dwarf Novae

57. Outburst and Post-Outburst Active Phase of the Black Hole X-ray Binary V4641 Sgr in 2002

58. Period change of Superhumps in the WZ Sge-Type Dwarf Nova, HV Virginis

59. In-the-Gap SU UMa-Type Dwarf Nova, Var73 Dra with a Supercycle of about 60 Days

60. WZ Sge-Type Star V592 Herculis

61. The 2001 Superoutburst of WZ Sagittae

64. Discovery and Photometric Observation of the Optical Counterpart in a Possible Galactic Halo X-ray Transient, XTE J1118+480

65. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials

67. P71 SGLT2I IN THE REAL WORLD: DATA FROM THE PONTE (BRIDGE) HF PROJECT (PDTA FOR INTEGRATED TERRITORY HOSPITAL FOLLOW–UP OF PATIENTS WITH HEART FAILURE)

70. Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA : Individual patient data pooled analysis of CRICKET and CAVE trials

71. Incidence and risk factors of esophagogastric varices bleeding in cirrhotic patients with advanced hepatocellular carcinoma treated with lenvatinib

72. OC.12.4 PROGNOSTIC FACTORS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH LENVATINIB

73. The ASAS-SN bright supernova catalogue – V. 2018–2020

76. Binary asteroid population. 3. Secondary rotations and elongations

77. ASASSN-15lh: A highly super-luminous supernova

78. Climate Change and Trend Analysis of 24-Hourly Annual Maximum Series Using Mann-Kendall and Sen Slope Methods for Rainfall IDF Modeling

82. 67P Real-world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

83. EE275 Personalised Versus Standard Dosimetry for Selective Internal Radiation Therapy in Patients With Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

84. 65P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population

85. 84P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population

86. 79P Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study

87. The ASAS-SN Bright Supernova Catalog -- V. 2018-2020

90. Physics of tearing mode rotation and slow-down in the RFX-mod tokamak

91. 59P Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications

92. 413P Primary tumor resection (PTR) in metastatic colorectal cancer (mCRC) patients (pts) treated with upfront chemotherapy (CT) + bevacizumab (BEV): A pooled analysis of TRIBE and TRIBE2 studies

93. Transcriptome signatures from discordant sibling pairs reveal changes in peripheral blood immune cell composition in Autism Spectrum Disorder

94. Improving Indian meteorological department method for 24- hourly rainfall downscaling to shorter durations for IDF modelling

97. Predictive Performance Analysis of PDF – IDF Model Types Using Rainfall Observations from Fourteen Gauged Stations

98. O-7 Evidence of therapeutic effectiveness of third-line cetuximab rechallenge in appropriately selected patients: Findings from long-term follow-up of CRICKET and CAVE trials

99. O-5 Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study

100. SO-14 Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study

Catalog

Books, media, physical & digital resources